Table 3.
Clinical features of patients infected with different EVs on admission in this study.
| EV types | All | CVA6 | CVA2 | CVA5 | CVA16 |
|---|---|---|---|---|---|
| No. of patients | N = 361 | N = 173 | N = 32 | N = 25 | N = 84 |
| Fever (≥37.5°C) | 327 (90.6%) | 164 (94.8%) | 31 (96.9%) | 24 (96.0%) | 64 (76.2%)# |
| High Fever (≥39°C) | 205 (56.8%) | 109 (63.0%) | 27 (84.4%) | 16 (64.0%) | 27 (32.1%)# |
| Antiadoncus | 145 (40.2%) | 103 (59.5%) | 21 (65.6%) | 19 (76.0%) | 54 (64.3%) |
| Neurologic complications | 60 (16.6%) | 33/173 (19.1%) | 5/32 (15.6%) | 6/25 (24.0%) | 5/84 (6.0%)# |
| No. of patients | N = 60 | N = 33 | N = 5 | N = 6 | N = 5 |
| Startle reaction | 29 (48.3%) | 22 (66.7%) | 0 (0.0%) | 2 (33.3%)a | 5 (100.0%) |
| Twitching | 19 (31.7%) | 13 (39.4%) | 4 (80.0%) | 4 (66.7%) | 0 (0.0%) |
| Hand and foot trembling | 2 (3.3%) | 1 (3.0%) | 1 (20.0%) | 0 (0.0%) | 0 (0.0%) |
| Vomiting | 3 (5.0%) | 1 (3.0%) | 1 (20.0%) | 1 (16.7%) | 0 (0.0%) |
| Severe cases | 60 (16.6%) | 33/173 (19.1%) | 5/32 (15.6%) | 6/25 (24.0%) | 5/84 (6.0%)# |
a
CVA5 vs. CVA16, P were < 0.05.
#
Compared with CVA6, CVA2, and CVA5 groups, P were < 0.05.